Androgen receptor immunoexpression in triple-negative breast cancers: is it a prognostic factor?

Zaborowski, Matthew; Pearson, A. Scott; Sioson, Loretta; Gill, Anthony J.; Ahadi, Mahsa

doi:10.1016/j.pathol.2018.09.063

Cited by 5 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In some trials, patients with TNBC with AR expression had a better prognosis [12][13][14][15][16][17][18][19][20] ; however, others indicated that AR positivity was associated with poor prognosis. [21][22][23][24][25][26] In addition, in several studies, [27][28][29][30][31][32][33][34][35][36][37][38] it was illustrated that AR expression did not correlate with the prognosis of TNBC.…”

Section: Introductionmentioning

confidence: 99%

“…39,40 In a previous meta-analysis, it was confirmed that AR positivity was associated with a lower risk of disease recurrence. 41 However, studies [12][13][14][15][21][22][23]27,28,32,[34][35][36][37][38] assessing the connection of AR expression and its prognostic value have recently been published, and have added to the inconsistent evidence. According to the Cochrane Handbook for Systematic Reviews of Interventions, 42 the meta-analysis should be updated every 2 years.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic Significance of Androgen Receptor Expression in Triple Negative Breast Cancer: A Systematic Review and Meta-Analysis

Yuan

Yan

et al. 2020

Clinical Breast Cancer

View full text Add to dashboard Cite

The androgen receptor (AR) is increasingly considered as a potential biomarker for breast cancer. Nevertheless, the prognostic value of AR expression in patients with triple negative breast cancer (TNBC) remains controversial. Therefore, in this meta-analysis, we investigated AR expression and its impact on survival outcome. PubMed, Embase, the Cochrane Library, and references of articles were searched to identify relevant studies that investigated the association between AR expression and prognosis in patients diagnosed with TNBC and were published between 1946 and May 2019. The hazard ratio (HR) and confidence interval (CI) of disease-free survival, overall survival, distant disease-free survival, and recurrence-free survival were weighted and pooled by using the fixed-effect or randomeffect model based on the heterogeneity of included studies. A total of 27 studies including 4914 patients with TNBC were included. AR was expressed in 27.96% (1315/4703) of patients with TNBC. In addition, AR expression in TNBC was not associated with disease-free survival (HR, 0.923; 95% CI, 0.671-1.271; P ¼ .634), overall survival (HR, 0.910; 95% CI, 0.678-1.222; P ¼ .531), distant disease-free survival (HR, 1.02; 95% CI, 0.96-1.08; P ¼ .489), or recurrence-free survival (HR, 0.957; 95% CI, 0.462-1.982; P ¼ .906) in TNBC, regardless of confounding factors and heterogeneity that existed among included studies. In patients with TNBC, AR expression is not associated with prognosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Prognostic Significance of Androgen Receptor Expression in Triple Negative Breast Cancer: A Systematic Review and Meta-Analysis

Yuan

Yan

et al. 2020

Clinical Breast Cancer

View full text Add to dashboard Cite

show abstract

“…Clinical identification of AR positive tumours is traditionally determined by calculating the H-score for nuclear expression only, where H-score is determined by the sum of [1 × (% cells 1+) + 2 × (% cells 2+) + 3 × (% cells 3+)] 37 . To investigate the utility of cytoplasmic AR (Cyt-AR) as a prognostic marker for disease outcome in TNBC, we defined the H-score for Cyt-AR and nuclear AR (Nuc-AR) in 308 patient samples from two independent, treatment-naive TNBC cohorts and determined their relationship to survival outcome 38, 39 .…”

Section: Resultsmentioning

confidence: 99%

Targeting phenotypic plasticity prevents metastasis and the development of chemotherapy-resistant disease

Juan

Hediyeh-Zadeh

Rangel

et al. 2022

Preprint

View full text Add to dashboard Cite

Cancer cells invoke phenotypic plasticity programs to drive disease progression and evade chemotherapeutic insults, yet until now there have been no validated clinical therapies targeting this process. Here, we identify a phenotypic plasticity signature associated with poor survival in basal/triple-negative breast cancer, in which androgen signalling is prominent. We establish that anti-androgen therapies block cancer stem cell function and prevent chemotherapy-induced emergence of new cancer stem cells. In particular, the anti-androgen agent seviteronel synergizes with chemotherapy to improve chemotherapeutic inhibition of primary and metastatic tumour growth and prevent the emergence of chemotherapy-resistant disease. We validate cytoplasmic AR expression as a clinical phenotypic plasticity biomarker that predicts poor survival and poor response to chemotherapy, and positive response to seviteronel plus chemotherapy. This new targeted combination therapy validates modulating phenotypic plasticity as an effective strategy to prevent and treat chemotherapy-resistant cancers with transformative clinical potential.

show abstract

“…The clinical characteristics and androgen receptor status of this cohort have been previously reported. 8 We performed pan-NTRK immunohistochemistry using a commercially available rabbit monoclonal antibody (clone EPR17341; Abcam, USA; dilution 1/50, after heat induced antigen retrieval in an alkaline retrieval solution) using similar methods to that reported by others. 6 The TMA sections stained with NTRK were scored by two independent observers who were blinded to all clinical and pathological details.…”

mentioning

confidence: 99%

Is secretory breast carcinoma underdiagnosed? In the era of targeted therapy should there be a low threshold to screen for NTRK immunohistochemistry in triple negative breast cancers?

Zaborowski

Gill²

2019

Pathology

Self Cite

View full text Add to dashboard Cite

Androgen receptor immunoexpression in triple-negative breast cancers: is it a prognostic factor?

Cited by 5 publications

References 9 publications

Prognostic Significance of Androgen Receptor Expression in Triple Negative Breast Cancer: A Systematic Review and Meta-Analysis

Prognostic Significance of Androgen Receptor Expression in Triple Negative Breast Cancer: A Systematic Review and Meta-Analysis

Targeting phenotypic plasticity prevents metastasis and the development of chemotherapy-resistant disease

Is secretory breast carcinoma underdiagnosed? In the era of targeted therapy should there be a low threshold to screen for NTRK immunohistochemistry in triple negative breast cancers?

Contact Info

Product

Resources

About